BioCardia finds alternative funding solution

The California biotech is conducting a reverse merger to help fund a late-stage study. 

By Lisa LaMotta • Aug. 24, 2016

Pfizer continues dealmaking with antibiotics buy

The pharma giant will pay as much as $1.6 billion for AstraZeneca's small-molecule anti-infectives portfolio. 

By Ned Pagliarulo • Aug. 24, 2016

DS Biopharma creates fibrotic spin out

The privately held biotech is creating a new company to focus on fibrotic diseases. 

By Lisa LaMotta • Aug. 23, 2016

Pfizer wins Medivation with $14B bid

The big pharma adds to its cancer portfolio with a highly sought-after acquisition. 

By Lisa LaMotta • Aug. 22, 2016

Roche, Eleven Bio eye the ocular market

The pair team up on the biotech's IL-6 antagonist in a deal worth $270 million. 

By Nicole Gray • Aug. 19, 2016

Bayer, CRISPR christen Casebia

The big pharma and the biotech reveal the details of the joint venture they established late last year. 

By Lisa LaMotta • Aug. 19, 2016

FDA expedites Aspen's prostate drug ahead of merger

The newly merged company will provide women's health, men's health and OTC products. 

By Nicole Gray • Aug. 18, 2016

Trek Therapeutics in-licenses Medivir hep C drug

 The agreement includes development and commercialization and has a global purview, with the exception of China, Taiwan, Hong Kong and Macai.

By Nicole Gray • Aug. 18, 2016

Rasna Therapeutics taps public market with merger

The new company will trade on NASDAQ-OTC under the ticker ATVM.

By Nicole Gray • Aug. 18, 2016

Tioma lands $86M Series A for immunotherapy

Formerly known as Vasculox, the biotech pulled in a large funding round to support its CD47 checkpoint inhibitor program. 

By Lisa LaMotta • Aug. 16, 2016

Mallinckrodt plans regen med acquisition

The UK specialty pharma has entered into a merger agreement with a privately-held regenerative medicine company. 

By Nicole Gray • Aug. 12, 2016

Gilead licenses bi-specific tech from Danish biotech Genmab

The major biotech hopes to develop a bi-specific antibody targeting HIV using Genmab's DuoBody platform.

By Nicole Gray • Aug. 12, 2016

Allergan makes a buy, but not the one you think

Despite receiving an influx of over $33 billion in cash from the Teva deal, Allergan CEO Brent Saunders has indicated his preference for "stepping stone" deals. 

By Lisa LaMotta • Aug. 11, 2016

Medivation bullish on Xtandi as PDUFA approaches

CEO David Hung stayed mum on contract negotiations with potential suitors during the recent quarterly call. 

By Nicole Gray • Aug. 11, 2016

AstraZeneca bolsters stake in Moderna by $140 million

As a result of the new equity investment, AstraZeneca now owns a 9% share in the messenger RNA company.

By Nicole Gray • Aug. 11, 2016

Biogen's hemophilia spinoff has a shiny new name

Bioverativ, named after its Biogen roots and the word 'veracity', is set to debut on public markets during the first half of 2017. 

By Lisa LaMotta • Aug. 10, 2016

Swiss Helsinn picks up late-stage cancer drug from MEI Pharma

Known for its supportive care products, Helsinn hopes to expand into drug development. 

By Nicole Gray • Aug. 9, 2016

Sanofi, Boehringer bank on strength through consolidation

The two companies have been given the OK to move forward with their asset swap, provided they sell off some assets. 

By Lisa LaMotta • Aug. 5, 2016

Teva bolsters generics consolidation with purchase of Allergan's distributor

Teva will pay Allergan $500 million for Anda Inc., the fourth largest wholesale distributor of generics in the U.S.

By Edwin Lopez • Aug. 4, 2016

Inovio going it alone after Roche departure

The biotech vows to continue development of its hepatitis B drug after Roche bowed out of the partnership. 

By Lisa LaMotta • Aug. 3, 2016

Takeover rumors juice Biogen stock, but fade fast

According to a report, Merck and Allergan have informally approached Biogen about a potential sale, spurring a stock jump of 9% Tuesday.

By Ned Pagliarulo • Aug. 3, 2016

Pfizer addresses speculation about divorce

The pharma giant is not showing its cards regarding a potential split of the company, but instead talked strategy and taxes during its Q2 call.

By Lisa LaMotta • Aug. 2, 2016

Amgen secures rights to cancer immunotherapy from biotech Advaxis

Advaxis believes its technology will allow for more personalized treatment of cancer than existing drugs.

By Ned Pagliarulo • Aug. 2, 2016

Pfizer buys Bamboo for $150 million, bets on gene therapy

The deal, potentially worth $645 million if all milestones are met, gives Pfizer full ownership of the company, its pipeline, and a dedicated manufacturing facility in North Carolina.

By Edwin Lopez • Aug. 1, 2016

Private equity firm Advent buys 50% stake in InVentiv

InVentiv, a major pharmaceutical contract company, said it would no longer pursue an IPO as a result of Advent's equity investment. 

By Nicole Gray • Aug. 1, 2016